SCHEMBL30714573

SCHEMBL30714573

Cn1nc2ccc(OCc3ccccn3)cc2c1C(=O)N[C@@H]1CCN(CCO)C1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.40
HPGDS O60760 1/20 0.37
MAPK14 Q16539 2/20 0.37
SMO Q99835 2/20 0.37
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
KMT2A Q03164 1/20 0.36
GRM5 P41594 1/20 0.36
GRM1 Q13255 1/20 0.36
PDE5A O76074 2/20 0.35
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30714705 1.00 MET (0.40) METHPGDSMAPK14SMOBRD4
SCHEMBL30714565 0.90 HTR3A (0.44) KDM4EALDH1A1HTR3A
SCHEMBL30714689 0.87 HPGDS (0.35) HPGDSKDM4EMEN1ALDH1A1CYP1A2
SCHEMBL31539871 0.86 SCN9A (0.35) HPGDSKDM4EMEN1ALDH1A1CYP1A2
SCHEMBL30714675 0.83 SCN9A (0.35) HPGDSKDM4EMEN1ALDH1A1CYP1A2
SCHEMBL30714550 0.83 KDM4E (0.46) METMAPK14SMOKDM4EALDH1A1
SCHEMBL31539894 0.81 SMO (0.40) METMAPK14SMOBRD4CREBBP
SCHEMBL24485679 0.81 CASP3 (0.42) METMAPK14SMOKDM4EMEN1
SCHEMBL29630019 0.81 CASP3 (0.42) METMAPK14SMOKDM4EMEN1
SCHEMBL30714672 0.81 RAB9A (0.43) HPGDSMAPK14SMOBRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 MET 3785/4885HPGDS 671/4885MAPK14 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.